Chronic Hepatitis C Infection in Children

Advances in Pediatrics

Volumn 63, Issue 1, 2016, Pages 173-194

  Pham, Yen H ^a   Rosenthal, Philip ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Chronic hepatitis C; Direct acting antivirals; Hepatitis C virus; Pegylated interferon; Ribavirin; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; VIRUS RNA;

BLOOD; CHILD; CHRONIC HEPATITIS C; GENETICS; HEPACIVIRUS; HUMAN; PATHOGENICITY; TRANSMISSION;

ANTIVIRAL AGENTS; CHILD; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL;

EID: 84991628410     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2016.04.019     Document Type: Review

References (153)

1. [1] Webster, D.P., Klenerman, P., Dusheiko, G.M., Hepatitis C. Lancet 385:9973 (2015), 1124–1135.
2. [2] Gower, E., Estes, C., Blach, S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:1 Suppl (2014), S45–S57.
3. [3] Abu Faddan, N.H., Shehata, G.A., Abd Elhafeez, H.A., et al. Cognitive function and endogenous cytokine levels in children with chronic hepatitis C. J Viral Hepat 22:8 (2015), 665–670.
4. [4] Rodrigue, J.R., Balistreri, W., Haber, B., et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 48:3 (2009), 341–347.
5. [5] Nydegger, A., Srivastava, A., Wake, M., et al. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 23:2 (2008), 226–230.
6. [6] Foster, G.R., Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 16:9 (2009), 605–611.
7. [7] El-Shabrawi, M.H., Kamal, N.M., Burden of pediatric hepatitis C. World J Gastroenterol 19:44 (2013), 7880–7888.
8. [8] Hepatitis C virus infection. American academy of pediatrics. Committee on infectious diseases. Pediatrics 101:3 Pt 1 (1998), 481–485.
9. [9] Omland, L.H., Krarup, H., Jepsen, P., et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 53:1 (2010), 36–42.
10. [10] Jhaveri, R., Grant, W., Kauf, T.L., et al. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 148:3 (2006), 353–358.
11. [11] Nainan, O.V., Alter, M.J., Kruszon-Moran, D., et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the united states. Gastroenterology 131:2 (2006), 478–484.
12. [12] Sullivan, D.G., Bruden, D., Deubner, H., et al. Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. J Infect Dis 196:2 (2007), 239–248.
13. [13] Huang, H., Shiffman, M.L., Cheung, R.C., et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130:6 (2006), 1679–1687.
14. [14] Mosbruger, T.L., Duggal, P., Goedert, J.J., et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 201:9 (2010), 1371–1380.
15. [15] Bosi, I., Ancora, G., Mantovani, W., et al. HLA DR13 and HCV vertical infection. Pediatr Res 51:6 (2002), 746–749.
16. [16] Martinetti, M., Pacati, I., Cuccia, M., et al. Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus. Int J Immunopathol Pharmacol 19:2 (2006), 369–378.
17. [17] Bevilacqua, E., Fabris, A., Floreano, P., et al. Genetic factors in mother-to-child transmission of HCV infection. Virology 390:1 (2009), 64–70.
18. [18] Ruiz-Extremera, A., Munoz-Gamez, J.A., Salmeron-Ruiz, M.A., et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 53:6 (2011), 1830–1838.
19. [19] Mast, E.E., Hwang, L.Y., Seto, D.S., et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 192:11 (2005), 1880–1889.
20. [20] Shebl, F.M., El-Kamary, S.S., Saleh, D.A., et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol 81:6 (2009), 1024–1031.
21. [21] Yeung, L.T., To, T., King, S.M., et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat 14:11 (2007), 797–805.
22. [22] Luban, N.L., Colvin, C.A., Mohan, P., et al. The epidemiology of transfusion-associated hepatitis C in a children's hospital. Transfusion 47:4 (2007), 615–620.
23. [23] Zanetti, A.R., Tanzi, E., Paccagnini, S., et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 345:8945 (1995), 289–291.
24. [24] Okamoto, M., Nagata, I., Murakami, J., et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis 182:5 (2000), 1511–1514.
25. [25] Resti, M., Azzari, C., Mannelli, F., et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany study group on hepatitis C virus infection. BMJ 317:7156 (1998), 437–441.
26. [26] Moriya, T., Sasaki, F., Mizui, M., et al. Transmission of hepatitis C virus from mothers to infants: its frequency and risk factors revisited. Biomed Pharmacother 49:2 (1995), 59–64.
27. [27] Conte, D., Fraquelli, M., Prati, D., et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 31:3 (2000), 751–755.
28. [28] Claret, G., Noguera, A., Esteva, C., et al. Mother-to-child transmission of hepatitis C virus infection in Barcelona, Spain: a prospective study. Eur J Pediatr 166:12 (2007), 1297–1299.
29. [29] Mast, E.E., Mother-to-infant hepatitis C virus transmission and breastfeeding. Adv Exp Med Biol 554 (2004), 211–216.
30. [30] Yeung, L.T., King, S.M., Roberts, E.A., Mother-to-infant transmission of hepatitis C virus. Hepatology 34:2 (2001), 223–229.
31. [31] Granovsky, M.O., Minkoff, H.L., Tess, B.H., et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 102:2 Pt 1 (1998), 355–359.
32. [32] European Paediatric Hepatitis C Virus Network, A significant sex–but not elective cesarean section–effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 192:11 (2005), 1872–1879.
33. [33] Hurtado, C.W., Golden-Mason, L., Brocato, M., et al. Innate immune function in placenta and cord blood of hepatitis C–seropositive mother-infant dyads. PLoS One, 5(8), 2010, e12232.
34. [34] Yeung, C.Y., Lee, H.C., Chan, W.T., et al. Vertical transmission of hepatitis C virus: current knowledge and perspectives. World J Hepatol 6:9 (2014), 643–651.
35. [35] Ohto, H., Terazawa, S., Sasaki, N., et al. Transmission of hepatitis C virus from mothers to infants. the vertical transmission of hepatitis C virus collaborative study group. N Engl J Med 330:11 (1994), 744–750.
36. [36] Tajiri, H., Miyoshi, Y., Funada, S., et al. Prospective study of mother-to-infant transmission of hepatitis C virus. Pediatr Infect Dis J 20:1 (2001), 10–14.
37. [37] Steininger, C., Kundi, M., Jatzko, G., et al. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis 187:3 (2003), 345–351.
38. [38] Indolfi, G., Azzari, C., Resti, M., Perinatal transmission of hepatitis C virus. J Pediatr 163:6 (2013), 1549–1552.e1.
39. [39] Garcia-Tejedor, A., Maiques-Montesinos, V., Diago-Almela, V.J., et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur J Obstet Gynecol Reprod Biol 194 (2015), 173–177.
40. [40] Minola, E., Maccabruni, A., Pacati, I., et al. Amniocentesis as a possible risk factor for mother-to-infant transmission of hepatitis C virus. Hepatology 33:5 (2001), 1341–1342.
41. [41] Ducarme, G., Ceccaldi, P.F., Bernuau, J., et al. Amniocentesis and viral risk (hepatitis B, C virus and HIV). J Gynecol Obstet Biol Reprod (Paris) 38:6 (2009), 469–473.
42. [42] Shiraki, K., Ohto, H., Inaba, N., et al. Guidelines for care of pregnant women carrying hepatitis C virus and their infants. Pediatr Int 50:1 (2008), 138–140.
43. [43] Ferrero, S., Lungaro, P., Bruzzone, B.M., et al. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta Obstet Gynecol Scand 82:3 (2003), 229–234.
44. [44] Jara, P., Resti, M., Hierro, L., et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 36:3 (2003), 275–280.
45. [45] Ackerman, Z., Ackerman, E., Paltiel, O., Intrafamilial transmission of hepatitis C virus: a systematic review. J Viral Hepat 7:2 (2000), 93–103.
46. [46] Tohme, R.A., Holmberg, S.D., Is sexual contact a major mode of hepatitis C virus transmission?. Hepatology 52:4 (2010), 1497–1505.
47. [47] Mohamed, M.K., Magder, L.S., Abdel-Hamid, M., et al. Transmission of hepatitis C virus between parents and children. Am J Trop Med Hyg 75:1 (2006), 16–20.
48. [48] Ketzinel-Gilad, M., Colodner, S.L., Hadary, R., et al. Transient transmission of hepatitis C virus from mothers to newborns. Eur J Clin Microbiol Infect Dis 19:4 (2000), 267–274.
49. [49] Ceci, O., Margiotta, M., Marello, F., et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 33:5 (2001), 570–575.
50. [50] Iorio, R., Giannattasio, A., Sepe, A., et al. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 41:10 (2005), 1431–1437.
51. [51] Vogt, M., Lang, T., Frosner, G., et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 341:12 (1999), 866–870.
52. [52] Rerksuppaphol, S., Hardikar, W., Dore, G.J., Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 19:12 (2004), 1357–1362.
53. [53] Bortolotti, F., Verucchi, G., Camma, C., et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 134:7 (2008), 1900–1907.
54. [54] Casiraghi, M.A., De Paschale, M., Romano, L., et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 39:1 (2004), 90–96.
55. [55] Guido, M., Rugge, M., Jara, P., et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 115:6 (1998), 1525–1529.
56. [56] Cesaro, S., Bortolotti, F., Petris, M.G., et al. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer 55:1 (2010), 108–112.
57. [57] Indolfi, G., Guido, M., Azzari, C., et al. Histopathology of hepatitis C in children, a systematic review: implications for treatment. Expert Rev Anti Infect Ther 13:10 (2015), 1225–1235.
58. [58] Gonzalez-Peralta, R.P., Langham, M.R. Jr., Andres, J.M., et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 48:5 (2009), 630–635.
59. [59] Strickland, D.K., Jenkins, J.J., Hudson, M.M., Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol 23:8 (2001), 527–529.
60. [60] Rumbo, C., Fawaz, R.L., Emre, S.H., et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr 43:2 (2006), 209–216.
61. [61] Mohan, P., Colvin, C., Glymph, C., et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 150:2 (2007), 168–174 174.e1.
62. [62] Birnbaum, A.H., Shneider, B.L., Moy, L., Hepatitis C in children. N Engl J Med 342:4 (2000), 290–291.
63. [63] Madhoun, M.F., Fazili, J., Bright, B.C., et al. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci 339:2 (2010), 169–173.
64. [64] Lok, A.S., Seeff, L.B., Morgan, T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136:1 (2009), 138–148.
65. [65] Garazzino, S., Calitri, C., Versace, A., et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 173:8 (2014), 1025–1031.
66. [66] Delgado-Borrego, A., Healey, D., Negre, B., et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 51:2 (2010), 191–197.
67. [67] Delgado-Borrego, A., Jordan, S.H., Negre, B., et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 8:5 (2010), 458–462.
68. [68] Page, K., Hahn, J.A., Evans, J., et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200:8 (2009), 1216–1226.
69. [69] Serra, M.A., Escudero, A., Rodriguez, F., et al. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. J Clin Gastroenterol 36:2 (2003), 170–174.
70. [70] Wise, M., Finelli, L., Sorvillo, F., Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Public Health Rep 125:3 (2010), 414–422.
71. [71] Beech, B.M., Myers, L., Beech, D.J., Hepatitis B and C infections among homeless adolescents. Fam Community Health 25:2 (2002), 28–36.
72. [72] Murray, K.F., Richardson, L.P., Morishima, C., et al. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics 111:1 (2003), 153–157.
73. [73] Forton, D.M., Thomas, H.C., Murphy, C.A., et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35:2 (2002), 433–439.
74. [74] de Leuw, P., Sarrazin, C., Zeuzem, S., How to use virological tools for the optimal management of chronic hepatitis C. Liver Int 31:Suppl 1 (2011), 3–12.
75. [75] Mack, C.L., Gonzalez-Peralta, R.P., Gupta, N., et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 54:6 (2012), 838–855.
76. [76] Ghany, M.G., Strader, D.B., Thomas, D.L., et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:4 (2009), 1335–1374.
77. [77] England, K., Pembrey, L., Tovo, P.A., et al., European Paediatric HCV Network, Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers. Acta Paediatr 94:4 (2005), 444–450.
78. [78] Polywka, S., Pembrey, L., Tovo, P.A., et al. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 78:2 (2006), 305–310.
79. [79] Pokorska-Spiewak, M., Kowalik-Mikolajewska, B., Aniszewska, M., et al. Is liver biopsy still needed in children with chronic viral hepatitis?. World J Gastroenterol 21:42 (2015), 12141–12149.
80. [80] de Ledinghen, V., Wong, V.W., Vergniol, J., et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol 56:4 (2012), 833–839.
81. [81] Poynard, T., de Ledinghen, V., Zarski, J.P., et al. Performances of elasto-FibroTest((R)), a combination between FibroTest((R)) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 36:5 (2012), 455–463.
82. [82] El-Shabrawi, M.H., Mohsen, N.A., Sherif, M.M., et al. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest. Eur J Gastroenterol Hepatol 22:8 (2010), 946–951.
83. [83] Pawlowska, M., Domagalski, K., Pniewska, A., et al. What's new in hepatitis C virus infections in children?. World J Gastroenterol 21:38 (2015), 10783–10789.
84. [84] Sira, M.M., Behairy, B.E., Abd-Elaziz, A.M., et al. Serum inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) in children with chronic hepatitis C: relation to liver fibrosis and viremia. Hepat Res Treat, 2014, 2014, 307942.
85. [85] Yang, L., Rudser, K.D., Higgins, L., et al. Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Dig Dis Sci 56:11 (2011), 3305–3315.
86. [86] Behairy, B.E., El-Mashad, G.M., Abd-Elghany, R.S., et al. Serum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C. World J Hepatol 5:8 (2013), 445–451.
87. [87] NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 19:3 (2002), 1–46.
88. [88] Camarero, C., Ramos, N., Moreno, A., et al. Hepatitis C virus infection acquired in childhood. Eur J Pediatr 167:2 (2008), 219–224.
89. [89] Goodman, Z.D., Makhlouf, H.R., Liu, L., et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the PEDS-C trial. Hepatology 47:3 (2008), 836–843.
90. [90] El Sherbini, A., Mostafa, S., Ali, E., Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C. Aliment Pharmacol Ther 42:1 (2015), 12–19.
91. [91] Gonzalez-Peralta, R.P., Kelly, D.A., Haber, B., et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 42:5 (2005), 1010–1018.
92. [92] Schwarz, K.B., Gonzalez-Peralta, R.P., Murray, K.F., et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 140:2 (2011), 450–458.e1.
93. [93] Wirth, S., Pieper-Boustani, H., Lang, T., et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 41:5 (2005), 1013–1018.
94. [94] Wirth, S., Ribes-Koninckx, C., Calzado, M.A., et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 52:4 (2010), 501–507.
95. [95] Wirth, S., Lang, T., Gehring, S., et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 36:5 (2002), 1280–1284.
96. [96] Christensson, B., Wiebe, T., Akesson, A., et al. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 30:3 (2000), 585–586.
97. [97] Schwarz, K.B., Mohan, P., Narkewicz, M.R., et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 43:4 (2006), 499–505.
98. [98] Tsunoda, T., Inui, A., Etani, Y., et al. Efficacy of pegylated interferon-alpha2a monotherapy in Japanese children with chronic hepatitis C. Hepatol Res 41:5 (2011), 399–404.
99. [99] Lackner, H., Moser, A., Deutsch, J., et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics, 106(4), 2000, E53.
100. [100] Di Bisceglie, A.M., Shiffman, M.L., Everson, G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359:23 (2008), 2429–2441.
101. [101] Feld, J.J., Hoofnagle, J.H., Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:7053 (2005), 967–972.
102. [102] Bekisz, J., Schmeisser, H., Hernandez, J., et al. Human interferons alpha, beta and omega. Growth Factors 22:4 (2004), 243–251.
103. [103] Zeuzem, S., Feinman, S.V., Rasenack, J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:23 (2000), 1666–1672.
104. [104] Lindsay, K.L., Trepo, C., Heintges, T., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:2 (2001), 395–403.
105. [105] Ascione, A., De Luca, M., Tartaglione, M.T., et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 138:1 (2010), 116–122.
106. [106] McHutchison, J.G., Lawitz, E.J., Shiffman, M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361:6 (2009), 580–593.
107. [107] Rumi, M.G., Aghemo, A., Prati, G.M., et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 138:1 (2010), 108–115.
108. [108] Sporea, I., Danila, M., Sirli, R., et al. Comparative study concerning the efficacy of peg-IFN alpha-2a versus peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J Gastrointest Liver Dis 15:2 (2006), 125–130.
109. [109] Lau, J.Y., Tam, R.C., Liang, T.J., et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35:5 (2002), 1002–1009.
110. [110] Maag, D., Castro, C., Hong, Z., et al. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 276:49 (2001), 46094–46098.
111. [111] Crotty, S., Maag, D., Arnold, J.J., et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:12 (2000), 1375–1379.
112. [112] McHutchison, J.G., Gordon, S.C., Schiff, E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. hepatitis interventional therapy group. N Engl J Med 339:21 (1998), 1485–1492.
113. [113] Poynard, T., Marcellin, P., Lee, S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International hepatitis interventional therapy group (IHIT). Lancet 352:9138 (1998), 1426–1432.
114. [114] Sung, H., Chang, M., Saab, S., Management of hepatitis C antiviral therapy adverse effects. Curr Hepat Rep 10:1 (2011), 33–40.
115. [115] Abdel-Aziz, D.H., Sabry, N.A., El-Sayed, M.H., et al. Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study. J Pharm Pract 24:2 (2011), 203–210.
116. [116] Ong, J.P., Younossi, Z.M., Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 71:Suppl 3 (2004), S17–S21.
117. [117] Sulkowski, M.S., Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 9:4 (2005), 601–616 vi.
118. [118] Yamane, A., Nakamura, T., Suzuki, H., et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 112:3 (2008), 542–550.
119. [119] Pockros, P.J., Duchini, A., McMillan, R., et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 97:8 (2002), 2040–2045.
120. [120] Dourakis, S.P., Deutsch, M., Hadziyannis, S.J., Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 25:6 (1996), 972–975.
121. [121] De Franceschi, L., Fattovich, G., Turrini, F., et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31:4 (2000), 997–1004.
122. [122] Al-Huthail, Y.R., Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: a review. Saudi J Gastroenterol 12:2 (2006), 59–67.
123. [123] Indolfi, G., Bartolini, E., Serranti, D., et al. Hepatitis C in children co-infected with human immunodeficiency virus. J Pediatr Gastroenterol Nutr 61:4 (2015), 393–399.
124. [124] Mofenson, L.M., Brady, M.T., Danner, S.P., et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 58:RR-11 (2009), 1–166.
125. [125] Soriano, V., Puoti, M., Sulkowski, M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS 21:9 (2007), 1073–1089.
126. [126] Tural, C., Galeras, J.A., Planas, R., et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther 13:8 (2008), 1047–1055.
127. [127] Zampino, R., Marrone, A., Merola, A., et al. Long-term outcome of hepatitis B and hepatitis C virus co-infection and single HBV infection acquired in youth. J Med Virol 81:12 (2009), 2012–2020.
128. [128] Pokorska-Spiewak, M., Kowalik-Mikolajewska, B., Aniszewska, M., et al. The influence of hepatitis B and C virus coinfection on liver histopathology in children. Eur J Pediatr 174:3 (2015), 345–353.
129. [129] Harmatz, P., Jonas, M.M., Kwiatkowski, J.L., et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica 93:8 (2008), 1247–1251.
130. [130] Vezali, E., Aghemo, A., Colombo, M., A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 32:13 (2010), 2117–2138.
131. [131] Everson, G.T., Trotter, J., Forman, L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42:2 (2005), 255–262.
132. [132] Ferrell, L.D., Wright, T.L., Roberts, J., et al. Hepatitis C viral infection in liver transplant recipients. Hepatology 16:4 (1992), 865–876.
133. [133] Barshes, N.R., Udell, I.W., Lee, T.C., et al. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl 12:7 (2006), 1119–1123.
134. [134] Mohamad, B., Hanouneh, I.A., Zein, N.N., et al. Liver transplant in young adults with chronic hepatitis C virus: an argument for hepatitis C treatment in childhood. Exp Clin Transplant 14:2 (2016), 201–206.
135. [135] Arango, J., Arbelaez, M., Henao, J., et al. Kidney graft survival in patients with hepatitis C: a single center experience. Clin Transplant 22:1 (2008), 16–19.
136. [136] Pereira, B.J., Natov, S.N., Bouthot, B.A., et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The new England organ bank hepatitis C study group. Kidney Int 53:5 (1998), 1374–1381.
137. [137] Schmitz, V., Kiessling, A., Bahra, M., et al. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant 12:3 (2007), 22–27.
138. [138] Baid, S., Cosimi, A.B., Tolkoff-Rubin, N., et al. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 70:2 (2000), 255–261.
139. [139] Baid, S., Tolkoff-Rubin, N., Saidman, S., et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 3:1 (2003), 74–78.
140. [140] Bell, T.W., Drugs for hepatitis C: unlocking a new mechanism of action. ChemMedChem 5:10 (2010), 1663–1665.
141. [141] Bacon, B.R., Gordon, S.C., Lawitz, E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:13 (2011), 1207–1217.
142. [142] Jacobson, I.M., Pawlotsky, J.M., Afdhal, N.H., et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 19:Suppl 2 (2012), 1–26.
143. [143] Susser, S., Welsch, C., Wang, Y., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:6 (2009), 1709–1718.
144. [144] Chou, R., Hartung, D., Rahman, B., et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 158:2 (2013), 114–123.
145. [145] Reddy, K.R., Bourliere, M., Sulkowski, M., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62:1 (2015), 79–86.
146. [146] Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:16 (2014), 1483–1493.
147. [147] Jacobson, I.M., Gordon, S.C., Kowdley, K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368:20 (2013), 1867–1877.
148. [148] Lawitz, E., Jacobson, I.M., Nelson, D.R., et al. Development of sofosbuvir for the treatment of hepatitis C virus infection. Ann N Y Acad Sci 1358:1 (2015), 56–67.
149. [149] Zeuzem, S., Dusheiko, G.M., Salupere, R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370:21 (2014), 1993–2001.
150. [150] Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370:3 (2014), 211–221.
151. [151] Everson, G.T., Sims, K.D., Rodriguez-Torres, M., et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146:2 (2014), 420–429.
152. [152] Zeuzem, S., Jacobson, I.M., Baykal, T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:17 (2014), 1604–1614.
153. [153] Khatri, A., Menon, R.M., Marbury, T.C., et al. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. J Hepatol 63:4 (2015), 805–812.